Effect of Oxyjun™ on Adipose Tissue Inflammation - A Randomized, Placebo-Controlled Clinical Study

The aim of the study was to evaluate the effect of OxyjunTM on cardiovascular fitness of overweight individuals by reducing obesity induced systemic inflammation. Male participants between the ages of 18 35 years and body mass index of 25 34.9 kg/m were recruited in the study. Change in neutrophil lymphocyte ratio (NLR), high density lipoprotein (HDL-c) and quality of life using 36-item Short form survey (SF-36) was assessed over a period of 8-weeks. Results demonstrated that NLR was reduced by 0.71 in OxyjunTM and by 0.42 in the placebo group at the end of study period. Also, within group comparison was significant for OxyjunTM group when compared from baseline; p<0.001. Further, HDL-c levels were increased in the Oxyjun group by 4.04 mg/dL and reduced for the placebo group by 1.22 mg/dL when compared from baseline; p=0.09. For SF-36 quality of life assessments, the health concepts of fatigue, mental health, and social function showed significant improvement and no adverse or serious adverse events were reported for both groups during the course of the study. In conclusion, OxyjunTM when consumed for 8-weeks reduced NLR of study volunteers thereby demonstrating its potential for lowering obesity induced systemic inflammation. OxyjunTM also increased HDL levels that could further promote cardiovascular fitness and prevent the risk of cardiovascular events.